Rifaximin ameliorates influenza A virus infection-induced lung barrier damage by regulating gut microbiota
Open Access
- 19 September 2024
- journal article
- research article
- Published by Springer Nature in Applied Microbiology and Biotechnology
- Vol. 108 (1) , 1-16
Abstract
Prior research has indicated that the gut-lung-axis can be influenced by the intestinal microbiota, thereby impacting lung immunity. Rifaximin is a broad-sKeywords
Funding Information
- National Natural Science Foundation of China (32272992)
- Xinjiang Animal Disease Prevention and Control Engineering Technology Research Center (GC2021003)
This publication has 33 references indexed in Scilit:
- Symbiotic Bacterial Metabolites Regulate Gastrointestinal Barrier Function via the Xenobiotic Sensor PXR and Toll-like Receptor 4Immunity, 2014
- Mucosal Barrier, Bacteria and Inflammatory Bowel Disease: Possibilities for TherapyDigestive Diseases, 2014
- Characterization of a Novel Influenza Virus in Cattle and Swine: Proposal for a New Genus in the Orthomyxoviridae FamilymBio, 2014
- Microbiota-Dependent Crosstalk Between Macrophages and ILC3 Promotes Intestinal HomeostasisScience, 2014
- Pulmonary-intestinal cross-talk in mucosal inflammatory diseaseMucosal Immunology, 2011
- Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22Nature Immunology, 2011
- Influenza A Inhibits Th17-Mediated Host Defense against Bacterial Pneumonia in MiceThe Journal of Immunology, 2011
- CD4+ Lymphoid Tissue-Inducer Cells Promote Innate Immunity in the GutImmunity, 2011
- Rifaximin pharmacology and clinical implicationsExpert Opinion on Drug Metabolism & Toxicology, 2009
- Influenza Virus Not cRAFTy Enough to Dodge ViperinCell Host & Microbe, 2007